Home/Pipeline/HDP-103

HDP-103

Prostate Cancer

PreclinicalActive

Key Facts

Indication

Prostate Cancer

Phase

Preclinical

Status

Active

Company

Heidelberg Pharma

About Heidelberg Pharma

Heidelberg Pharma is a clinical-stage biotech focused on revolutionizing cancer therapy through its proprietary ATAC (Antibody Targeted Amanitin Conjugate) technology platform. The company's mission is to create 'inspired medicines that matter to cancer patients' by targeting drug-resistant and quiescent tumor cells, a significant unmet need. Its strategy combines advancing internal clinical assets, such as HDP-101 for multiple myeloma, with a partnership-driven model to out-license its platform, generating non-dilutive funding. Recent achievements include securing milestone payments from partners and amending a royalty financing agreement to strengthen its balance sheet.

View full company profile

Therapeutic Areas

Oncology

Other Prostate Cancer Drugs

Drug	Company	Phase	Status
APVO442	Aptevo Therapeutics	Preclinical	Active
APVO452	Aptevo Therapeutics	Discovery	Active
BIO 300	Humanetics Corp.	Not Specified	Active
Opaganib	RedHill Biopharma	Phase 2	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
CROES Registry	AngioDynamics	Post-Market Registry	Active
Cannabics® PRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC
ENV105	Kairos Pharma	Phase 2	Active
AI for Prostate Cancer	Invenio Imaging	Research	Active
Mitomic™ Test for Prostate Cancer	MDNA Life Sciences	Development/Validation	Active
Immunomodulator Platform	OmniCyte	Research	Active